Tenecteplase for COVID-19: real-time analysis

Download Image

Post

c19early.org

Tenecteplase for COVID-19

1 study with 13 patients

Serious outcome risk

Tenecteplase

Control

No significant improvements are seen in meta-analysis to date.

COVID-19 Tenecteplase studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−25%

Mortality (1)−25%

Hospitalization (1)15%

RCTs (1)−25%

Late (1)−25%

00.511.5+

← Tenecteplase
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

Tenecteplase is a recombinant tissue plasminogen activator (tPA) and fibrinolytic agent that dissolves blood clots by converting plasminogen to plasmin.


Feb 16 2024	Poor et al., Cureus, doi:10.7759/cureus.54298	Tenecteplase With Concomitant Anticoagulation for Acute Respiratory Failure in Patients With COVID-19: A Randomized Controlled Trial
Feb 16 2024	25% higher mortality (p=1), 38% lower progression (p=0.59), and 15% shorter hospitalization (p=0.82). RCT 13 hospitalized COVID-19 patients with acute respiratory failure showing no significant difference in mortality or respiratory outcomes with tenecteplase plus heparin versus placebo plus heparin. At 28 days, 63% of tenecteplase patien..